# ARA-290 Philippines: Cibinetide Research Guide Source: https://www.philippinespeptides.com/peptides/ara290 Updated: 2026-09-24 > ARA-290 (cibinetide) Philippines guide: an erythropoietin-derived peptide studied in small human trials in neuropathy. Side effects and registration status. On this page - [What is ARA-290](#what) - [How it works](#how) - [On the ground in the Philippines](#ph-context) - [Benefits studied](#benefits) - [Side effects reported](#side-effects) - [Regulatory status](#regulatory) - [Who should not use ARA-290](#contraindications) - [FAQ](#faq) - [Where to get ARA-290 in the Philippines](#sourcing) - [Primary sources](#sources) Recovery · Compound # ARA-290 Philippines Peptides editorial desk Updated 24 September 2026 Trial data checked 23 September 2026 6 min read 5 sources **Class** - Tissue-protection research ARA-290 is not yet in the evidence datasets this site draws on, so this page makes no claim about what it does. ## What is ARA-290 ARA-290 (also known as cibinetide) is a peptide derived from the region of erythropoietin (EPO) that binds the tissue-protective, or innate repair, receptor. In cell and animal studies (Brines 2008, PNAS), peptides of this kind were tissue-protective without stimulating red blood cell production. Browse the full [peptide library](https://www.philippinespeptides.com/peptides) for related compounds. In people, ARA-290 has been studied in small human trials: one in patients with sarcoidosis and symptoms of small fiber neuropathy (Heij 2012, Mol Med), and one in patients with type 2 diabetes that reported improvements in metabolic control and neuropathic symptoms (Brines 2015, Mol Med). A 2013 review (Niesters et al.) covers the sarcoidosis neuropathic pain research. These are small studies, and ARA-290 is not in the evidence datasets this site draws on. Our partner and supplier If you decide to source research peptides Research vials are not approved for human use, are sold for research only, and must be reconstituted. - Stocked in Metro Manila; same-day delivery there for orders before 12 noon - Lab report: Janoshik, batch RETA-4728-A, retatrutide, bacterial endotoxin only; not identity or purity. Key [H2KI86I8GWB4](https://verify.janoshik.com/tests/234146_H2KI86I8GWB4), [batch reports](https://www.primaralabs.com/coa?utm_source=philippinespeptides&utm_medium=referral&utm_campaign=bridge&utm_content=ara290) - [60-day money-back guarantee](https://www.primaralabs.com/guarantee?utm_source=philippinespeptides&utm_medium=referral&utm_campaign=bridge&utm_content=ara290) - GCash, Maya, QR Ph bank transfer, InstaPay Primara Labs is our partner and supplier. ## How it works Innate repair receptor: ARA-290 was engineered to act on the tissue-protective (innate repair) receptor rather than the EPO receptor that drives red blood cell production. This design rests on cell and animal work (Brines 2008). Tissue protection: in the same cell and animal studies, activating the tissue-protective receptor was associated with protection of tissue from injury. These are animal and cell findings. ## On the ground in the Philippines ARA-290 (cibinetide) had no Philippine drug registration in the FDA Philippines registered drug products database when it was checked on 7 May 2026. ## Benefits studied ARA-290 is not yet in the evidence datasets this site draws on, so this page makes no claim about what it does. Anything published about it elsewhere should be read with its evidence level in mind: most peptides in this category have animal or cell data only. ## Side effects reported No controlled human data on adverse events for ARA-290 is in the datasets this site draws on, so its safety in people is unknown rather than established. Effects commonly described for it are listed below; how often they occur has not been measured in a controlled trial. - Injection site reactions - Headache - Fatigue - Dizziness - Elevated blood pressure ## Regulatory status The regulatory dataset this site draws on has no row for ARA-290. ## Who should not use ARA-290 Do not use if - Active cancer - History of thromboembolic disease - Pregnancy or breastfeeding - Severe hypertension Everything above is research framing. If you have got as far as wanting a vial, the catalogue at Primara Labs, our partner and supplier, is the shortest way to see what is held inside the Philippines and at what price. [View the Primara Labs catalogue](https://www.primaralabs.com/marketplace?utm_source=philippinespeptides&utm_medium=referral&utm_campaign=inline) Primara Labs, our partner and supplier, stocks its research catalogue in Metro Manila. Research use only. ## FAQ ### Is ARA-290 the same as EPO (erythropoietin)? No. ARA-290 is a peptide engineered from a small region of the EPO molecule. In cell and animal studies (Brines 2008, PNAS), peptides of this kind acted on the tissue-protective receptor without stimulating red blood cell production. ### Has ARA-290 been studied in diabetic neuropathy? Yes. A small human trial in patients with type 2 diabetes (Brines 2015, Mol Med) reported improvements in metabolic control and neuropathic symptoms. It is a small study, and ARA-290 is not in the evidence datasets this site draws on, so no trial figure is shown on this page. ### What evidence exists for ARA-290? Small human trials plus cell and animal work. The sources cited on this page are a trial in sarcoidosis patients with small fiber neuropathy symptoms (Heij 2012), a trial in type 2 diabetes with neuropathic symptoms (Brines 2015), a review of the sarcoidosis neuropathic pain research (Niesters 2013) and the cell and animal work behind its design (Brines 2008). ### Is ARA-290 registered in the Philippines? ## Where to get ARA-290 in the Philippines Primara Labs, our partner and supplier, lists their current vials on the catalogue. Prices and stock change, so check there for what is available now. [View the Primara Labs catalogue](https://www.primaralabs.com/marketplace?utm_source=philippinespeptides&utm_medium=referral&utm_campaign=inline) Our partner and supplier ### Sourcing peptides in the Philippines Primara Labs, our partner and supplier, ships from inventory already inside the Philippines, so there is no customs leg: vials are batch-numbered, Metro Manila orders dispatch same day, the rest of the country lands in 1 to 5 business days, and the store lists 10% off every order. The current list sits on one page, and anything you cannot see on it goes through the same WhatsApp thread. The supply index covers what to ask a seller before paying, and why quoted prices vary so widely. [View Supply Index](https://www.philippinespeptides.com/supply) ## Primary sources Citations supporting the clinical claims on this page. Each entry links to the primary record. - 1. Tissue-protective EPO-derived peptides: Brines 2008 Mechanism Brines M, Patel NSA, Villa P, et al. "Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin." PNAS 2008;105(31):10925–10930. [DOI: 10.1073/pnas.0805594105](https://doi.org/10.1073/pnas.0805594105) - 2. Sarcoidosis small-fiber neuropathy trial: Heij 2012 Trial Heij L, Niesters M, Swartjes M, et al. "Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy." Mol Med 2012;18(1):1430–1436. [DOI: 10.2119/molmed.2012.00332](https://doi.org/10.2119/molmed.2012.00332) - 3. Type 2 diabetes neuropathy trial: Brines 2015 Trial Brines M, Dunne AN, van Velzen M, et al. "ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes." Mol Med 2015;20(1):658–666. [DOI: 10.2119/molmed.2014.00215](https://doi.org/10.2119/molmed.2014.00215) - 4. ARA-290 in sarcoidosis-induced chronic neuropathic pain: Niesters 2013 Review Niesters M, Swartjes M, Heij L, et al. "The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain." Expert Opin Orphan Drugs 2013;1(1):77–87. [DOI: 10.1517/21678707.2013.719289](https://doi.org/10.1517/21678707.2013.719289) - 5. FDA Philippines drug registry: ARA-290 not listed Reference FDA Philippines Registered Drug Products Database. Verified 2026-05-07: ARA-290 / cibinetide has no Philippine drug registration; available only as research-grade peptide. [Source](https://verification.fda.gov.ph/) How this was gathered Findings, evidence levels and sources are from the Research Desk datasets published by [Primara Labs, our partner and supplier](https://www.primaralabs.com/research/evidence?utm_source=philippinespeptides&utm_medium=referral&utm_campaign=inline), synced 23 September 2026 and summarised here in this site’s own words. Risk · Disclosure · Editorial Status This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician (ideally one with peptide-specific clinical experience) before starting any compound, adjusting a dose, or discontinuing therapy. In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale. **Editorial Status** - Non-clinical **Affiliation** - Not a clinic · Not a pharmacy **Last Updated** - September 24, 2026 ### Related peptides - [Compound BPC-157](https://www.philippinespeptides.com/peptides/bpc157) - [Compound TB-500](https://www.philippinespeptides.com/peptides/tb500) - [Compound KPV](https://www.philippinespeptides.com/peptides/kpv) - [Compound SS-31](https://www.philippinespeptides.com/peptides/ss31) --- Philippines Peptides sells nothing. Primara Labs is our partner and supplier. This is general information, not medical or legal advice.